Top Markets
Coin of the day
PCI Biotech Holding ASA PCI Biotech Holding ASA

PCI Biotech Holding ASA

PCIB
Rangering i aksjer #40012
PCI Biotech Holding ASA, an Oslo, Norway-based biopharmaceutical firm, is... PCI Biotech Holding ASA, an Oslo, Norway-based biopharmaceutical firm, is focused on pioneering and bringing to market innovative treatments for cancer. At the core of their operations is the proprietary photochemical internalization (PCI) technology platform. The company's development pipeline features several distinct therapeutic strategies: fimaCHEM, a novel approach to chemotherapeutic cancer treatment; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is currently in Phase I clinical studies; and fimaNAc, a delivery system for nucleic acid therapeutics, presently in its pre-clinical phase. Furthermore, they provide Amphinex, a photosensitizer known as fimaporfin. PCI Biotech actively participates in joint research endeavors with partners such as Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense.
Aksjekurs
$0.00733708
Sist synkronisert: 2026-04-23
Markedsverdi
$273.87K
Endring (1 dag)
-39.13%
Endring (1 år)
-94.83%
Land
NO
Handel PCI Biotech Holding ASA (PCIB)

Kategori

Inntekter for PCI Biotech Holding ASA (PCIB)
Inntekter i 2026 TTM: 0
Ifølge PCI Biotech Holding ASA sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for PCI Biotech Holding ASA fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE